Home blood transfusions in hospice for people with blood cancers
Tests home blood transfusions in hospice for adults with blood cancers.
Plain-language title generated from the registry record
Registry title: HEME Home Transfusion Program
Key facts
- Where
- Boston, United StatesSee the 2 sites
Where in United States
- Brigham and Women's HospitalBoston, United StatesTaking people
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Dana-Farber Cancer Institute
- Trial code
- NCT06487247
- Record updated
- 28 October 2026
- Original description
This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.Read full original descriptionShow less
Supportive Transfusion Program for Patients With Hematologic Malignancies: A Cluster Randomized Trial
This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.
Inclusion: Diagnosis of a relapsed/refractory hematologic malignancy; Age ≥ 18 years; Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment); Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction; Patient resides within catchment served by Care Dimensions Hospice; Physician-estimated prognosis of six months or less; Identified informal caregiver of enrolled patient with hematologic malignancy; Age ≥ 18 years.
Exclusion: History of previous serious adverse transfusion reaction; Age < 18 years; -Age < 18 years; Already enrolled in hospice; Resides in nursing home or assisted living facility.